Although predictors of acute intraprocedural stent thrombosis (IPST) in the drug-eluting stent era have been proposed, external validation is lacking. We thus analyzed the occurrence of IPST in the RECIPE study and found that, among 1,320 patients who underwent drug-eluting stent implantation, IPST occurred in 6 (0.5%), with in-hospital major adverse events in 4 (67%). IPST was predicted by number and total length of implanted stents, baseline minimal lumen diameter, and, in a pooled analysis that incorporated values from the present study and a previous study, use of elective glycoprotein IIb/IIIa inhibitors. Such results may provide useful information to guide prevention of this complication. (c) 2005 by Excerpta Medica Inc.
Validation of predictors of intraprocedural stent thrombosis in the drug-eluting stent era / BIONDI ZOCCAI, Giuseppe; Giuseppe M., Sangiorgi; Alaide, Chieffo; Guido, Vittori; Elena, Falchetti; Massimo, Margheri; Rossella, Barbagallo; Corrado, Tamburino; Enrico, Remigi; Carlo, Briguori; Ioannis, Iakovou; Pierfrancesco, Agostoni; Elephteria, Tsagalou; Gloria, Melzi; Iassen, Michev; Flavio, Airoldi; Matteo, Montorfano; Mauro, Carlino; Antonio, Colombo; Recipe Study, Investigators. - In: THE AMERICAN JOURNAL OF CARDIOLOGY. - ISSN 0002-9149. - STAMPA. - 95:12(2005), pp. 1466-1468. [10.1016/j.amjcard.2005.01.099]
Validation of predictors of intraprocedural stent thrombosis in the drug-eluting stent era
BIONDI ZOCCAI, GIUSEPPE;
2005
Abstract
Although predictors of acute intraprocedural stent thrombosis (IPST) in the drug-eluting stent era have been proposed, external validation is lacking. We thus analyzed the occurrence of IPST in the RECIPE study and found that, among 1,320 patients who underwent drug-eluting stent implantation, IPST occurred in 6 (0.5%), with in-hospital major adverse events in 4 (67%). IPST was predicted by number and total length of implanted stents, baseline minimal lumen diameter, and, in a pooled analysis that incorporated values from the present study and a previous study, use of elective glycoprotein IIb/IIIa inhibitors. Such results may provide useful information to guide prevention of this complication. (c) 2005 by Excerpta Medica Inc.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
